302 related articles for article (PubMed ID: 21152689)
1. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract][Full Text] [Related]
2. PET/CT and choline: diagnosis and staging.
Farsad M; Schwarzenböck S; Krause BJ
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):343-53. PubMed ID: 23013664
[TBL] [Abstract][Full Text] [Related]
3. Non-FDG PET in the practice of oncology.
Caroli P; Nanni C; Rubello D; Alavi A; Fanti S
Indian J Cancer; 2010; 47(2):120-5. PubMed ID: 20448372
[TBL] [Abstract][Full Text] [Related]
4. The role of new PET tracers for lung cancer.
Szyszko TA; Yip C; Szlosarek P; Goh V; Cook GJ
Lung Cancer; 2016 Apr; 94():7-14. PubMed ID: 26973200
[TBL] [Abstract][Full Text] [Related]
5. PET and PET/CT studies of tumor tissue oxygenation.
Krause BJ; Beck R; Souvatzoglou M; Piert M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):28-43. PubMed ID: 16557202
[TBL] [Abstract][Full Text] [Related]
6. Non FDG PET.
Nanni C; Fantini L; Nicolini S; Fanti S
Clin Radiol; 2010 Jul; 65(7):536-48. PubMed ID: 20541653
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
8. PET/CT in prostate cancer: non-choline radiopharmaceuticals.
Castellucci P; Jadvar H
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):367-74. PubMed ID: 23013666
[TBL] [Abstract][Full Text] [Related]
9. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging (PET) of brain tumors.
Basu S; Alavi A
Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
[TBL] [Abstract][Full Text] [Related]
11. PET tracers in musculoskeletal disease beyond FDG.
Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
[TBL] [Abstract][Full Text] [Related]
12. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
13. Serum tumor markers and PET/CT imaging for tumor recurrence detection.
Kruse V; Cocquyt V; Borms M; Maes A; Van de Wiele C
Ann Nucl Med; 2013 Feb; 27(2):97-104. PubMed ID: 23420146
[TBL] [Abstract][Full Text] [Related]
14. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.
Barwick T; Bencherif B; Mountz JM; Avril N
Nucl Med Commun; 2009 Dec; 30(12):908-17. PubMed ID: 19794320
[TBL] [Abstract][Full Text] [Related]
15. [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].
Couturier O; Leost F; Campone M; Carlier T; Chatal JF; Hustinx R
Bull Cancer; 2005 Sep; 92(9):789-98. PubMed ID: 16203269
[TBL] [Abstract][Full Text] [Related]
16. FDG PET and PET/CT.
Krause BJ; Schwarzenböck S; Souvatzoglou M
Recent Results Cancer Res; 2013; 187():351-69. PubMed ID: 23179888
[TBL] [Abstract][Full Text] [Related]
17. PET and PET-CT. State of the art and future prospects.
Fanti S; Franchi R; Battista G; Monetti N; Canini R
Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
19. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
20. [18F]FLT-PET in oncology: current status and opportunities.
Been LB; Suurmeijer AJ; Cobben DC; Jager PL; Hoekstra HJ; Elsinga PH
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1659-72. PubMed ID: 15565331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]